再次穿刺活检在转移性去势抵抗前列腺癌中的应用研究

doi:10.3969/j.issn.1006-6233.2018.12.025

Abstract
Figure/Table
References
Related Citation (5)

Download: PDF (1357 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the clinical significance of secondary prostate biopsy in metastatic castration-resistant prostate cancer (CRPC). Methods: 63 patients with CRPC in our hospital from July 2014 to July 2017 were randomly selected as the research subjects. All patients underwent secondary prostate biopsy. According to the secondary puncture results, the patients were divided into the combined intra-canal carcinoma (IDC-P) group (43 cases) and the unconsolidated IDC-P group (20 cases). The levels of prostate-specific antigen (PSA) and related parameters at the time of first puncture and second puncture were compared between the two groups. The follow up and prognosis of the patients were observed. Results: The first puncture results showed that 13 cases had IDC-P and 50 cases had normal adenocarcinoma. The second puncture results showed 43 cases had IDC-P and 20 cases had normal adenocarcinoma. The PSA, PSAD and PSATZ were (14.28 (+2.39) ng/mL, (0.26 (+0.41) ng/mL and (0.65 (+0.86) ng/mL respectively at the first puncture. At the second puncture, they were (17.32±2.73) ng/mL, (0.43±0.49) ng/mL, (0.99±1.01) ng/mL, respectively. The difference was statistically significant (t=70.968, 16.867, 17.991, P<0.05). The levels of PSA, PSAD, and PSATZ in the combined IDC-P group were (19.39±3.18) ng/mL, (0.57±0.52) ng/mL, and (1.27±1.03) ng/mL, respectively. Higher than the uncombined IDC-P group (15.26±2.59) ng/mL, (0.30±0.39) ng/mL, (0.71±0.81) ng/mL. The difference was statistically significant (t=5.072, 2.064, 2.140, P<0.05). At the mean follow-up (23.65±4.52) months, 11 patients died, and 52 patients (34 patients with IDC-P combined) received chemotherapy after the diagnosis of CRPC. There were 7 patients (20.59%) who had treatment responders in patients with IDC-P and 12 patients (66.67%) who had not responded to IDC-P. The difference between the two groups was statistically significant (χ²=10.777, P<0.05). Conclusion: The second biopsy is beneficial to the clinical understanding of the changes of metastatic prostate cancer (IDC-P) in a timely manner and has important guiding value for the treatment and prognosis of CRPC.

Key words： Needle biopsy Prostatic carcinoma Intraductal carcinoma of the prostate Prostate-specific antigen

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Shuai
	GAO Fan
	LIN Tao

Cite this article:

WANG Shuai,GAO Fan,LIN Tao. Application of Re-puncture Biopsy in Metastatic Castration-resistant Prostate Cancer[J]. HeBei Med, 2018, 24(12): 2037-2039.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.12.025 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I12/2037

[1] 冯静,廖绍光,程惠华,等.沙利度胺联合化疗治疗骨转移去势抵抗性前列腺癌的疗效观察[J].中国癌症杂志,2017,27(4):287~292.
[2] Rescigno P, Lorente D, Bianchini D, et al. Impact of PTEN protein loss on response to docetaxel and overall survival (OS) in metastatic castration resistant prostate cancer (mCRPC) patients[J]. European Journal of Cancer, 2015, 51(1):S496~S496. .
[3] 冯瑶,王晓微,朱春莲.前列腺癌患者穿刺活检引发感染性休克的原因分析及护理[J].中华现代护理杂志,2015,21(11):1276~1278.
[4] 李飞,朱彦锋,陈静瑶,等.染料木黄酮对去势抵抗前列腺癌22RV1细胞增殖的影响[J].郑州大学学报(医学版),2017,52(4):393~398.
[5] Mckay R R, Werner L, Mostaghel E A, et al. A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2017, 23(4):935~945. .
[6] Mcdaniel A S, Ferraldeschi R, Krupa R, et al. Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer[J]. Bju International, 2017, 120(5B):E30~E44. .
[7] 陈智彬,沈朋飞,曾浩,等.二次穿刺活检在去势抵抗性前列腺癌(CRPC)诊治中的意义[J].中国男科学杂志,2016,30(1):30~33.
[8] Boker A, Kuczyk M A, Kramer M W, et al. True Incidence of Gleason 6 Pathology in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC).[J]. Advances in Therapy, 2017, 34(1):171~179.
[9] Zhao J, Shen P, Sun G, et al. The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy.[J]. Oncotarget, 2017, 8(33):55374~55383. .
[10] 黄泓玮,孙永得,李建华,等.人前列腺癌组织中ALKBH3及VEGF-C蛋白的表达[J].郑州大学学报(医学版),2016,51(3):356~358.
[11] 朱逸飞,曾浩.前列腺癌干细胞与去势抵抗性前列腺癌放射性耐受的研究进展[J].中华放射肿瘤学杂志,2017,26(11):1347~1349.
[12] Sowalsky A G, Xia Z, Wang L, et al. Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer[J]. Molecular Cancer Research Mcr,2015,13(1):98~106.
[13] Theil G, Weiss C, Fischer K, et al. Abstract 3929: Heterogeneity in circulating tumor cells in blood samples of metastatic castration-resistant prostate cancer patient: comparison of isolation technique[J]. European Urology Supplements,2016,15(3):e733~e733. .
[14] 陈磊,王韧,白文坤,等.PSA相关指标在前列腺重复穿刺活检中的诊断价值[J].医学研究杂志,2016,45(12):89~92.